Medpage Today on MSN14h
Gene-Editing Therapy Reduced Attacks in Hereditary Angioedema
A single dose of the CRISPR-based gene-editing therapy NTLA-2002 reduced angioedema attacks and led to sustained reduction in ...
CRISPR-Cas9 gene editing trial results support further development as treatment for hereditary angioedema
A single treatment with a CRISPR-Cas9 based gene editing therapy is enough to replace the daily medication of patients with ...
Intellia slips after mid-stage data for CRISPR-based hereditary angioedema therapy
Intellia Therapeutics (NTLA) stock fell ~9% in reaction to Phase 2 trial data for a CRISPR-based gene editing therapy for ...
healthday2h
ACAAI: Gene-Editing Therapy Reduces Angioedema Attacks in Hereditary Angioedema
For adults with hereditary angioedema, the in vivo gene-editing therapy NTLA-2002, which is based on clustered regul ...
Intellia data spark debate about CRISPR drug’s potential
Newly published data show the therapy reduced the rate of swelling attacks in people with hereditary angioedema, but didn't ...
FierceBiotech1h
Poseida's HAE gene therapy edits primate livers and reduces kallikrein protein levels in mice, company says
Poseida Therapeutics’ gene therapy for hereditary angioedema (HAE) reduced kallikrein protein activity in a mouse model of ...
Poseida Therapeutics to present data on P-KLKB1-101 in hereditary angioedema
Poseida Therapeutics (PSTX) announced the upcoming presentation of new preclinical data supporting the potential of P-KLKB1-101, a ...
technologynetworks2h
CRISPR-Cas9 Therapy Shows Promise As Single-Dose Treatment for Hereditary Angioedema
Researchers expand on their phase one study demonstrating a single treatment with a CRISPR-Cas9-based gene editing therapy, ...
EurekAlert!6h
Phase Two results with CRISPR-Cas9 gene editing support further development as treatment for hereditary angioedema (HAE)
A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful ...
Armed robbery in Revesby6h
CRISPR-Cas9 Phase 2 Boosts Hereditary Angioedema Hope
A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with ...
FierceBiotech5h
Intellia links in vivo CRISPR therapy to 81% drop in HAE attacks in phase 2
Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, ...
Intellia's Ntla-2002 Shows Promising Results, but Stock Drops Following Phase 2 Data Release
Failed to import article template. Reason: Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app ...